{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:53:04Z","timestamp":1787590384760,"version":"build-2736575974"},"reference-count":129,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Type I interferons (IFN-Is) are important players in the immunopathogenesis of systemic lupus erythematosus (SLE). Pathogenic events in patients with SLE are potent triggers of IFN-I induction, yet IFN-I may induce or initiate the immunopathogenesis leading to these events. Because blocking IFN-I is effective in some clinical manifestations of SLE patients, concerns about the efficacy of anti-IFN-I therapy in patients with lupus nephritis remain. Tissues from kidney biopsies of patients with lupus nephritis revealed infiltration of various immune cells and activation of inflammatory signals; however, their correlation with renal damage is not clear, which raises serious concerns about how critical the role of IFN-I is among the potential contributors to the pathogenesis of lupus nephritis. This review addresses several issues related to the roles of IFN-I in SLE, especially in lupus nephritis, including (1) the contribution of IFN-I to the development and immunopathogenesis of SLE; (2) evidence supporting the association of IFN-I with lupus nephritis; (3) therapies targeting IFN-I and IFN-I downstream signaling molecules in SLE and lupus nephritis; (4) findings challenging the therapeutic benefits of anti-IFN-I in lupus nephritis; and (5) a perspective associated with anti-IFN-I biologics for lupus nephritis treatment. In addition to providing clear pictures of the roles of IFN-I in SLE, especially in lupus nephritis, this review addresses the lately published observations and clinical trials on this topic.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1489205","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T04:47:46Z","timestamp":1729054066000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Therapeutically targeting proinflammatory type I interferons in systemic lupus erythematosus: efficacy and insufficiency with a specific focus on lupus nephritis"],"prefix":"10.3389","volume":"15","author":[{"given":"Benjamin","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shue-Fen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenn-Haung","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex260","article-title":"The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies","volume":"56","author":"Rees","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60128-8","article-title":"Systemic lupus erythematosus","volume":"384","author":"Lisnevskaia","year":"2014","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11926-022-01063-9","article-title":"Mitochondria in the pathogenesis of systemic lupus erythematosus","volume":"24","author":"Chen","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.952398","article-title":"Glucose metabolism and glycosylation link the gut microbiota to autoimmune diseases","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101921-042422","article-title":"Systemic lupus erythematosus pathogenesis: interferon and beyond","volume":"41","author":"Caielli","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/art.20254","article-title":"Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG","volume":"50","author":"Lovgren","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.132","article-title":"Neutrophils in the pathogenesis and manifestations of SLE","volume":"7","author":"Kaplan","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.06.002","article-title":"Amyloid-DNA composites of bacterial biofilms stimulate autoimmunity","volume":"42","author":"Gallo","year":"2015","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155633","article-title":"Abnormalities of the type I interferon signaling pathway in lupus autoimmunity","volume":"146","author":"Gallucci","year":"2021","journal-title":"Cytokine"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215361","article-title":"Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals","volume":"78","author":"Jog","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-016-8550-y","article-title":"The role of STAT signaling pathways in the pathogenesis of systemic lupus erythematosus","volume":"52","author":"Goropevsek","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103477","article-title":"Expression characteristics of interferon-stimulated genes and possible regulatory mechanisms in lupus patients using transcriptomics analyses","volume":"70","author":"Deng","year":"2021","journal-title":"EBioMedicine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.immuni.2020.04.015","article-title":"Plasmacytoid dendritic cells and type I interferon promote extrafollicular B cell responses to extracellular self-DNA","volume":"52","author":"Soni","year":"2020","journal-title":"Immunity"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2016.10.006","article-title":"Plasmacytoid dendritic cells in autoimmunity","volume":"44","author":"Panda","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1186\/ar2887","article-title":"Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNalpha antibody, in systemic lupus erythematosus","author":"Yao","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201343806","article-title":"Self-priming determines high type I IFN production by plasmacytoid dendritic cells","volume":"44","author":"Kim","year":"2014","journal-title":"Eur J Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2010.02.014","article-title":"Human plasmacytoid dendritic cell accumulation amplifies their type 1 interferon production","volume":"136","author":"Liao","year":"2010","journal-title":"Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.01.005","article-title":"Impaired DNA methylation and its mechanisms in CD4(+)T cells of systemic lupus erythematosus","volume":"41","author":"Zhang","year":"2013","journal-title":"J Autoimmun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.08.010","article-title":"Type I interferon in systemic lupus erythematosus and other autoimmune diseases","volume":"25","author":"Banchereau","year":"2006","journal-title":"Immunity"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-004-1024-2","article-title":"Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C","volume":"24","author":"Niewold","year":"2005","journal-title":"Clin Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E","article-title":"Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy","volume":"43","author":"Ioannou","year":"2000","journal-title":"Arthritis Rheum"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/art.22578","article-title":"Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus","volume":"56","author":"Nzeusseu Toukap","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221835","article-title":"Serum interferon-alpha levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity","volume":"81","author":"Chasset","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9440(10)61689-6","article-title":"Plasmacytoid dendritic cells (natural interferon- alpha\/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions","volume":"159","author":"Farkas","year":"2001","journal-title":"Am J Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2012(02)11","article-title":"Clinical and serological manifestations associated with interferon-alpha levels in childhood-onset systemic lupus erythematosus","volume":"67","author":"Postal","year":"2012","journal-title":"Clinics (Sao Paulo)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"6149","DOI":"10.1038\/s41467-020-19918-z","article-title":"Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity","volume":"11","author":"Psarras","year":"2020","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00826-z","article-title":"Emerging concepts of type I interferons in SLE pathogenesis and therapy","volume":"18","author":"Psarras","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0398-x","article-title":"The immune cell landscape in kidneys of patients with lupus nephritis","volume":"20","author":"Arazi","year":"2019","journal-title":"Nat Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210066","article-title":"Decipher the immunopathological mechanisms and set up potential therapeutic strategies for patients with lupus nephritis","volume":"24","author":"Tsai","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900742","article-title":"Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis","volume":"183","author":"Fairhurst","year":"2009","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/art.30187","article-title":"Network analysis of associations between serum interferon-alpha activity, autoantibodies, and clinical features in systemic lupus erythematosus","volume":"63","author":"Weckerle","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1056\/NEJM197907053010102","article-title":"Immune interferon in the circulation of patients with autoimmune disease","volume":"301","author":"Hooks","year":"1979","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.237","article-title":"Type I interferons: crucial participants in disease amplification in autoimmunity","volume":"6","author":"Hall","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319885447","article-title":"Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures","volume":"28","author":"Brohawn","year":"2019","journal-title":"Lupus"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000270","article-title":"Interferon pathway in SLE: one key to unlocking the mystery of the disease","volume":"6","author":"Ronnblom","year":"2019","journal-title":"Lupus Sci Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac140","article-title":"Interferons and systemic lupus erythematosus: Pathogenesis, clinical features, and treatments in interferon-driven disease","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2012.07.008","article-title":"The genetics of type I interferon in systemic lupus erythematosus","volume":"24","author":"Bronson","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213386","article-title":"Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status","volume":"77","author":"Md Yusof","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000086","article-title":"Advances in lupus genetics and epigenetics","volume":"26","author":"Deng","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.2008.01146.x","article-title":"Genetic association of interferon-alpha subtypes 1, 2 and 5 in systemic lupus erythematosus","volume":"72","author":"Hirankarn","year":"2008","journal-title":"Tissue Antigens"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/science.1074900","article-title":"Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection","volume":"297","author":"Nguyen","year":"2002","journal-title":"Science"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/art.41532","article-title":"Type I interferon-activated STAT4 regulation of follicular helper T cell-dependent cytokine and immunoglobulin production in lupus","volume":"73","author":"Dong","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/art.42435","article-title":"Down-regulation-resistant STAT4 risk haplotype contributes to lupus nephritis through CD4+ T cell interferon-gamma production","volume":"75","author":"Madera-Salcedo","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2013.866105","article-title":"Ultraviolet B irradiation induces skin accumulation of plasmacytoid dendritic cells: a possible role for chemerin","volume":"47","author":"Yin","year":"2014","journal-title":"Autoimmunity"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1384606","article-title":"Interferon alpha promotes caspase-8 dependent ultraviolet light-mediated keratinocyte apoptosis via interferon regulatory factor 1","volume":"15","author":"Loftus","year":"2024","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10825.x","article-title":"The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score","volume":"166","author":"Braunstein","year":"2012","journal-title":"Br J Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02806.x","article-title":"Pathogenesis of subacute cutaneous lupus erythematosus","volume":"22","author":"Stavropoulos","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.71","article-title":"Interferon-alpha and -beta in kidney inflammation","volume":"77","author":"Anders","year":"2010","journal-title":"Kidney Int"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.02.031","article-title":"Type I interferon-related kidney disorders","volume":"101","author":"Lodi","year":"2022","journal-title":"Kidney Int"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/ni1136","article-title":"Bone marrow plasmacytoid dendritic cells can differentiate into myeloid dendritic cells upon virus infection","volume":"5","author":"Zuniga","year":"2004","journal-title":"Nat Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101313","article-title":"Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing","volume":"188","author":"Simmons","year":"2012","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.01.005","article-title":"Viruses evade the immune system through type I interferon-mediated STAT2-dependent, but STAT1-independent, signaling","volume":"22","author":"Hahm","year":"2005","journal-title":"Immunity"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.308","article-title":"Increased glomerular matrix metalloproteinase activity in murine lupus nephritis","volume":"74","author":"Tveita","year":"2008","journal-title":"Kidney Int"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2013.04.017","article-title":"The antiviral cytokines IFN-alpha and IFN-beta modulate parietal epithelial cells and promote podocyte loss: implications for IFN toxicity, viral glomerulonephritis, and glomerular regeneration","volume":"183","author":"Migliorini","year":"2013","journal-title":"Am J Pathol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2014.184","article-title":"Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease","volume":"10","author":"Kok","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-089086","article-title":"Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis","volume":"110","author":"Denny","year":"2007","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev311","article-title":"The frequency and outcome of lupus nephritis: results from an international inception cohort study","volume":"55","author":"Hanly","year":"2016","journal-title":"Rheumatol (Oxford)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: A systematic review and Bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23480","article-title":"Economic evaluation of lupus nephritis in the systemic lupus international collaborating clinics inception cohort using a multistate model approach","volume":"70","author":"Barber","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102490","article-title":"Are lupus animal models useful for understanding and developing new therapies for human SLE","volume":"112","author":"Moore","year":"2020","journal-title":"J Autoimmun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00306","article-title":"IFNalpha inducible models of murine SLE","volume":"4","author":"Liu","year":"2013","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1185727","article-title":"Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-alpha-accelerated lupus nephritis in mice","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.5.2499","article-title":"IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB\/c mice","volume":"174","author":"Mathian","year":"2005","journal-title":"J Immunol"},{"key":"B70","volume-title":"GCT, in The Autoimmune Diseases (Sixth Edition)","author":"Mizui","year":"2020"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1172\/JCI157272","article-title":"NLRP12 is an innate immune checkpoint for repressing IFN signatures and attenuating lupus nephritis progression","volume":"133","author":"Tsao","year":"2023","journal-title":"J Clin Invest"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653989","article-title":"EZH2 inhibition interferes with the activation of type I interferon signaling pathway and ameliorates lupus nephritis in NZB\/NZW F1 mice","volume":"12","author":"Wu","year":"2021","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1172\/JCI120288","article-title":"Inhibition of IRF5 hyperactivation protects from lupus onset and severity","volume":"130","author":"Song","year":"2020","journal-title":"J Clin Invest"},{"key":"B74","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.1038\/s41467-021-24609-4","article-title":"Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease","volume":"12","author":"Ban","year":"2021","journal-title":"Nat Commun"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2015.04.004","article-title":"Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL\/lpr mice","volume":"158","author":"Edwards","year":"2015","journal-title":"Clin Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0900615106","article-title":"IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model","volume":"106","author":"Zagury","year":"2009","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021996","article-title":"Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice","volume":"197","author":"Santiago-Raber","year":"2003","journal-title":"J Exp Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.5527\/wjn.v8.i7.109","article-title":"Broad spectrum of interferon-related nephropathies-glomerulonephritis, systemic lupus erythematosus-like syndrome and thrombotic microangiopathy: A case report and review of literature","volume":"8","author":"Gianassi","year":"2019","journal-title":"World J Nephrol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/art.22044","article-title":"Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus","volume":"54","author":"Feng","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0386-1","article-title":"Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways","volume":"20","author":"Der","year":"2019","journal-title":"Nat Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93009","article-title":"Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis","volume":"2","author":"Der","year":"2017","journal-title":"JCI Insight"},{"key":"B82","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13075-023-03094-8","article-title":"Renal interferon-inducible protein 16 expression is associated with disease activity and prognosis in lupus nephritis","volume":"25","author":"Wang","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac641","article-title":"Type I interferon and neutrophil transcripts in lupus nephritis renal biopsies: clinical and histopathological associations","volume":"62","author":"Mavragani","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02043-2","article-title":"Targeting interferon signalling in systemic lupus erythematosus: lessons learned","volume":"84","author":"Jones","year":"2024","journal-title":"Drugs"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17161","article-title":"An update on clinical trials for cutaneous lupus erythematosus","volume":"51","author":"Xie","year":"2024","journal-title":"J Dermatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/art.24557","article-title":"Neutralization of interferon-alpha\/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus","volume":"60","author":"Yao","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B88","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221425","article-title":"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials","volume":"81","author":"Vital","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225445","article-title":"Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials","volume":"83","author":"Baker","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S170969","article-title":"Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date","volume":"13","author":"Felten","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003302","article-title":"Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis","volume":"9","author":"Morand","year":"2023","journal-title":"RMD Open"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"Morand","year":"2023","journal-title":"Lancet"},{"key":"B98","article-title":"Efficacy and safety of abbv-599 high dose (elsubrutinib 60 mg and upadacitinib 30 mg) and upadacitinib monotherapy for the treatmen of systemic lupus erythematosus: a phase 2, double-blind, placebo-controlled trial","volume":"82","author":"Merrill JT","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: A phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00597-3","article-title":"Lupus nephritis: new and emerging biologic and targeted therapies","volume":"37","author":"Kale","year":"2023","journal-title":"BioDrugs"},{"key":"B101","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-000910","article-title":"Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial","volume":"10","author":"Jayne","year":"2023","journal-title":"Lupus Sci Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00317-9","article-title":"Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials","volume":"4","author":"Morand","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad089","article-title":"Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers","volume":"189","author":"Carter","year":"2023","journal-title":"Br J Dermatol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001007","article-title":"Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE","volume":"10","author":"Bao","year":"2023","journal-title":"Lupus Sci Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2023.2273536","article-title":"Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials","volume":"28","author":"Lim","year":"2023","journal-title":"Expert Opin Emerg Drugs"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30342-8","article-title":"Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study","volume":"3","author":"Bruce","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033753","article-title":"Type I interferon correlates with serological and clinical manifestations of SLE","volume":"64","author":"Dall'era","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B109","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13075-023-03010-0","article-title":"Relationship of systemic type I interferon activity with clinical phenotypes, disease activity, and damage accrual in systemic lupus erythematosus in treatment-naive patients: a retrospective longitudinal analysis","volume":"25","author":"Miyachi","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.063123","article-title":"Intrarenal cytokine gene expression in lupus nephritis","volume":"66","author":"Chan","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/art.30087","article-title":"Interferon-alpha accelerates murine systemic lupus erythematosus in a T cell-dependent manner","volume":"63","author":"Liu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200109)44:9<2097::AID-ART360>3.0.CO;2-6","article-title":"Predominance of Th1 immune response in diffuse proliferative lupus nephritis","volume":"44","author":"Masutani","year":"2001","journal-title":"Arthritis Rheum"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138345","article-title":"Integrated urine proteomics and renal single-cell genomics identify an IFN-gamma response gradient in lupus nephritis","volume":"5","author":"Fava","year":"2020","journal-title":"JCI Insight"},{"key":"B114","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000527223","article-title":"Comparative efficacy and safety of biological agents in the treatment of lupus nephritis: A network meta-analysis","volume":"108","author":"Lee","year":"2023","journal-title":"Pharmacology"},{"key":"B115","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/BOR.0000000000000577","article-title":"Neutrophils in lupus nephritis","volume":"31","author":"Nishi","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0909927107","article-title":"Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis","volume":"107","author":"Hakkim","year":"2010","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.676082","article-title":"IFN-I mediates lupus nephritis from the beginning to renal fibrosis","volume":"12","author":"Ding","year":"2021","journal-title":"Front Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100239","article-title":"PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps","volume":"207","author":"Li","year":"2010","journal-title":"J Exp Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92926","article-title":"Lupus and proliferative nephritis are PAD4 independent in murine models","volume":"2","author":"Gordon","year":"2017","journal-title":"JCI Insight"},{"key":"B120","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13075-022-02766-1","article-title":"Lupus nephritis correlates with B cell interferon-beta, anti-Smith, and anti-DNA: a retrospective study","volume":"24","author":"Alduraibi","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201477","article-title":"Anti-IFN-alpha\/beta receptor antibody treatment ameliorates disease in lupus-predisposed mice","volume":"189","author":"Baccala","year":"2012","journal-title":"J Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004111014","article-title":"Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice","volume":"16","author":"Schwarting","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy125","article-title":"Immune gene expression in kidney biopsies of lupus nephritis patients at diagnosis and at renal flare","volume":"34","author":"Mejia-Vilet","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309105529","article-title":"Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus","volume":"18","author":"Petri","year":"2009","journal-title":"Lupus"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230063","article-title":"Commensal bacteria promote type I interferon signaling to maintain immune tolerance in mice","volume":"221","author":"Vasquez Ayala","year":"2024","journal-title":"J Exp Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abi4994","article-title":"Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis","volume":"13","author":"Scherlinger","year":"2021","journal-title":"Sci Transl Med"},{"key":"B127","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.clim.2018.08.013","article-title":"Cytokine targets in lupus nephritis: Current and future prospects","volume":"206","author":"Adamichou","year":"2019","journal-title":"Clin Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"B129","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/art.42657","article-title":"Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial","volume":"76","author":"Saxena","year":"2024","journal-title":"Arthritis Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1489205\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T04:47:49Z","timestamp":1729054069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1489205\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":129,"alternative-id":["10.3389\/fimmu.2024.1489205"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1489205","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"article-number":"1489205"}}